“Smart Drugs”, Modafinil is suitable for specific people, improving their performance in complex and long-term tasks, improving decision-making and planning skills. Modafinil is also known under the brand name Provigil and has been given a pass by the FDA (Food and Drug Administration) for the curing of sleep disorders such as narcolepsy. However, like the students who accompany lectures on the exam, most addicts think it might help them focus and use it off the label. Although, there is no convincing evidence that the drug actually works in this way.
Recent studies show that cognitive tests are more complex than before, and the results show that Modafinil will definitely improve thinking. This is an ethical problem with Modafinil, especially if students have an unfair advantage in preparing for and participating in the exam.
Previous research has shown a variety of findings regarding the effects of Modafinil on healthy and underdeveloped individuals. However, researchers examined 24 placebo-controlled studies published between 1990 and 2014.The researchers found that Modafinil only improved certain cognitive characteristics. In general, the drug appears to enhance the executive purpose, capability to find new info and develop plans on its basis. The researchers also found that Modafinil also improved their ability to pay attention to learning and memory to a certain extent. Scientists have found that the drug does not consistently help participants with simple attention tests. Modanifil has little impact on the creativity and enthusiasm of the movement, which does not progress people’s working memory, tractability or capability to distract.
Modafinil has almost no side effects. Seventy percent of mood and side effect research studies found only insomnia, headache, abdominal pain and nausea. All these patients were also reported in the placebo group. This can be considered a cognitive stimulant. However, it is important to note that regardless of the method used to educate the public, ethical factors must always be taken into account.
Modafinil promotes awakening by an unknown mechanism of action. Compared with placebo, daytime sleep latency was significantly increased in patients with narcolepsy and excessive daytime sleepiness (EDS) was reduced. However, this drug does not inhibit cataplexy. Despite the lack of direct comparison data, Modafinil recompenses over amphetamine and methylphenidate in patients who have narcolepsy because of rebound lacking after treatment and its minimum prospective for abuse.
Patients with narcolepsy are known to tolerate Modanifil, and this is according to clinical trials. In addition to the significantly higher incidence of headaches reported in Modafinil recipients, the safety profile of 200-400 minigram per day of Modafinil was comparable to that of patients with placebo who were treated for 9 weeks.
Preliminary data show that lenience to Modafinil continues for a long duration almost (40 weeks). Although, Modafinil is operative in the management of EDS in patients that have narcolepsy, it is not operative against hemiplegia. Initial results show that, unlike other psychostimulants, abuse of substance is less expected to be connected with withdrawal symptoms. Thus, Modafinil can be a treatment that is effective and an option for narcolepsy patients.